Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101. doi: 10.1097/QAI.0b013e318259875b.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects*
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / etiology*
  • Dideoxynucleosides / administration & dosage
  • Dideoxynucleosides / adverse effects*
  • Fibrin Fibrinogen Degradation Products / metabolism
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • Interleukin-6 / blood
  • Longitudinal Studies
  • Risk Factors
  • Time Factors
  • Vascular Cell Adhesion Molecule-1 / blood

Substances

  • Anti-HIV Agents
  • Biomarkers
  • Dideoxynucleosides
  • Fibrin Fibrinogen Degradation Products
  • IL6 protein, human
  • Interleukin-6
  • Vascular Cell Adhesion Molecule-1
  • fibrin fragment D
  • C-Reactive Protein
  • abacavir